D-arginine-loaded metal-organic frameworks nanoparticles sensitize osteosarcoma to radiotherapy. (February 2021)

• Record Type: Journal Article
• Authors: Du, Chuanchao; Zhou, Mengxue; Jia, Fei; Ruan, Lifo; Lu, Huiru; Zhang, Jiayu; Zhu, Bin; Liu, Xiaoguang; Chen, Jun; Chai, Zhifang; Hu, Yi
• Is Part Of: Biomaterials. Volume 269(2021)
• Publication Date: 2021-02
• Subjects: Metal-organic frameworks -- D-arginine -- Osteosarcoma -- Radiotherapy -- Hypoxia; Biomedical materials -- Periodicals; Biocompatible Materials -- Periodicals; Biomatériaux -- Périodiques; 610.28
• DOI: 10.1016/j.biomaterials.2020.120642
• Languages: English
• ISSNs: 0142-9612

Abstract

Abstract: Osteosarcoma is a common type of bone cancers with a high rate of pulmonary recurrence. High-dose radiation therapy is useful for the ablation of unresectable osteosarcoma. However, it may cause severe adverse effects. To address this problem, we developed D-arginine-loaded metal-organic frameworks (MOF) nanoparticles for improving the radiosensitivity of osteosarcoma. D-arginine, a metabolically inert enantiomer of L-arginine, could produce nitric oxide and down-regulate hypoxia-inducible factor-1alpha (HIF-1α) to alleviate tumor hypoxia. In addition, MOF could also generate free radicals to kill the tumor cells. Results demonstrate that D-arginine-loaded nanoparticles enhanced tumor ablation and prevented the lung metastasis in mice upon radiation therapy. Furthermore, the nanoparticles or radiation alone had relatively low toxicity in cells and mice. Therefore, D-arginine-loaded MOF nanoparticles are relatively safe and highly effective in sensitizing osteosarcoma to radiotherapy.